Intermittent parathyroid hormone (PTH) treatment is a potent bone anabolic principle that suppresses expression of the bone formation inhibitor Sost. We addressed the relevance of Sost suppression for PTH-induced bone anabolism in vivo using mice with altered Sost gene dosage. Six-month-old Sost overexpressing and 2-month-old Sost deficient male mice and their wild-type littermates were subjected to daily injections of 100 mg/kg PTH(1-34) or vehicle for a 2-month period. A follow-up study was performed in Sost deficient mice using 40 and 80 mg/kg PTH(1-34). Animals were sacrificed 4 hours after the final PTH administration and Sost expression in long bone diaphyses was determined by qPCR. Bone changes were analyzed in vivo in the distal femur metaphysis by pQCT and ex vivo in the tibia and lumbar spine by DXA. Detailed ex vivo analyses of the femur were performed by pQCT, mCT, and histomorphometry. Overexpression of Sost resulted in osteopenia and Sost deletion in high bone mass. As shown before, PTH suppressed Sost in wild-type mice. PTH treatment induced substantial increases in bone mineral density, content, and cortical thickness and in aging wild-type mice also led to cancellous bone gain owing to amplified bone formation rates. PTH-induced bone gain was blunted at all doses and skeletal sites in Sost overexpressing and deficient mice owing to attenuated bone formation rates, whereas bone resorption was not different from that in PTH-treated wild-type controls. These data suggest that suppression of the bone formation inhibitor Sost by intermittent PTH treatment contributes to PTH bone anabolism. ß
Introduction
O steoporosis is a systemic skeletal disorder characterized by low bone mass and microarchitectural deterioration of bone tissue with a consequent increase in bone fragility and susceptibility to fracture. (1) It is characterized by a disturbed remodeling balance of bone resorbing osteoclasts and bone forming osteoblasts, resulting in a net decrease in bone mineral density (BMD). Most osteoporosis therapies are based on inhibition of bone catabolic osteoclast activity and hence can merely prevent further bone loss. The only clinically approved bone anabolic therapy, which can restore bone, is intermittent parathyroid hormone (PTH) treatment by daily injection. (2, 3) While it is an established bone forming principle, the underlying molecular mechanisms are only partially understood. PTH affects cells of the mesenchymal osteoblast lineage by signaling through the G-protein-coupled type 1 PTH/PTH-related peptide receptor (PTH1R). (4) It has been shown to increase osteoblast number by promoting osteoblastic precursor proliferation (5, 6) and reactivating quiescent bone lining cells, (7) as well as by stimulating osteoblast survival. (8, 9) In addition, intermittent PTH treatment enhances osteoblast differentiation and activity. (10) Finally, emerging evidence suggests a putative role for osteocytes in PTH-induced bone anabolism.
expression of Sost at the transcriptional level in a direct manner. (11, 12) Consistent with Sost encoding sclerostin, a secreted glycoprotein inhibiting bone formation, transgenic mice overexpressing human SOST exhibit a low bone mass phenotype. (19, 20) Conversely, constitutive Sost knockout (KO) mice lacking Sost expression display a high bone mass phenotype and increased bone strength. (21) Moreover, patients afflicted by sclerosteosis (MIM 269500) (22, 23) or van Buchem disease (MIM 239100) (24, 25) display lifelong bone overgrowth and a high bone mass phenotype with strongly increased bone mineral mass, density, and strength owing to loss of SOST expression.
The role of PTH signaling in osteocytes for the regulation of bone homeostasis was addressed recently by overexpressing a constitutively active PTH1R variant selectively in osteocytes. (13) Constitutively active PTH1R transgenic mice display increased bone mass and turnover and a concomitant reduction in Sost expression. These findings, together with the earlier observation that Sost is suppressed by PTH signaling, (11, 12) suggest that osteocytes might contribute to PTH-induced bone anabolism and that suppression of Sost may play a role in the bone anabolic activity of intermittent PTH treatment.
To address the relevance of Sost suppression for PTH-induced bone gain, we employed genetically engineered mouse models with altered Sost expression levels. We subjected SOST transgenic (SOST Tg) mice overexpressing human SOST and homozygous Sost KO mice lacking endogenous mouse Sost to 2 months of intermittent bone anabolic PTH treatment. We hypothesized that the contribution of suppression of Sost for PTH-induced bone anabolism might be reduced under conditions of increased Sost gene dosage. Likewise, we reasoned that if PTH-induced suppression of Sost contributes to PTHdependent bone anabolism in vivo, the bone anabolic response induced by intermittent PTH treatment should be attenuated in homozygous Sost KO mice, which lack Sost constitutively. Alternatively, if transient suppression of Sost is dispensable for PTH-induced bone anabolism in vivo, we expected to detect additive effects of Sost deficiency and intermittent PTH treatment. Here we report that PTH-induced bone anabolism is blunted in Sost overexpressing and deficient mice, suggesting that suppression of Sost contributes to PTH-induced bone gain in vivo.
Materials and Methods

Mice
The generation of SOST bacterial artificial chromosome (BAC) transgenic (SOST Tg) mice was described previously. (20) SOST Tg mice were maintained on a mixed FVB-C57BL/6 background. RNA extraction and quantitative real time PCR (qPCR) expression analyses
Total RNA was isolated from cortical bone of tibial or femoral diaphyses using TRIzol (Invitrogen, Karlsruhe, Germany) and RNeasy Mini (Qiagen, Hilden, Germany), as described previously, (11) and reverse-transcribed into cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Rotkreuz, Switzerland) according to the manufacturer's recommendations. Gene expression analyses were performed with an ABI Prism 7900HT sequence detection system (Applied Biosystems) using TaqMan Universal PCR Master Mix mouse or human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) TaqMan assay reagents for normalization and TaqMan probes for mouse and human Sost/SOST according to the manufacturer's instructions (Applied Biosystems).
Ex vivo dual-energy X-ray absorptiometry (DXA) analyses
The left tibia and lumbar vertebrae L1-4 were dissected, fixed for 24 hours in 4% phosphate-buffered paraformaldehyde, and stored in 70% ethanol. Tibial and lumbar spine BMD was measured in 70% ethanol for soft tissue calibration with a Hologic QDR-1000 instrument. A collimator with 0.9-cmdiameter aperture and an ultrahigh-resolution mode (line spacing 0.254 mm, resolution 0.127 mm) were employed. 
Results
Skeletal parameters of SOST Tg Tg mice and SOST expression Consistent with SOST encoding a bone formation inhibitor and previously reported findings, (20) SOST Tg male mice expressing wild-type human SOST from a bacterial artificial chromosome (BAC) transgene under control of the human genomic context develop osteopenia with increasing age (Fig. 1A, B) . Crosssectional total BMD in the distal femur metaphysis was significantly lower in SOST Tg relative to wild-type littermate males, as evaluated in vivo by pQCT analyses during late-stage skeletal growth (3 months of age) and during skeletal aging (see Fig. 1A ). Likewise, femoral cross-sectional cortical thickness was significantly decreased in aging SOST Tg mice compared with wild-type littermates (see Fig. 1B ). We then subjected 6-month-old SOST Tg mice and their wild-type littermate males to 2 months of intermittent PTH treatment using daily injections of 100 mg/kg hPTH(1-34) peptide. 4 hours after the final hPTH(1-34) application, the mice were sacrificed, and endogenous and transgenic Sost Fig. 1 . SOST overexpression results in osteopenia, and SOST is suppressed by PTH. Cross-sectional total BMD (A) and cortical thickness (B) in the distal femur metaphysis were evaluated by monthly in vivo pQCT measurements of skeletally mature to aging wild-type (white data points) and SOST Tg (filled data points) littermate male mice. Relative expression of endogenous mouse Sost (C) and transgenic human SOST (D) in cortical bone of the tibia diaphysis normalized to GAPDH with the corresponding DC t values indicated below the bars was determined by qPCR 4 hours following the final PTH (hatched bars) or vehicle (white bars) injection after 2 months of intermittent treatment with 100 mg/kg hPTH . Data represent means AE SEM. n.a. ¼ not applicable. expression was determined by qPCR. Similar to previous reports, (11, 12) endogenous Sost expression was suppressed by about 50% relative to vehicle-treated animals in cortical bone of PTH-treated 8-month-old wild-type and SOST Tg littermate mice (see Fig. 1C ). Moreover, human SOST expressed from the BAC transgene in SOST Tg mice was significantly suppressed 4 hours after the last hPTH(1-34) injection, comparable with endogenous mouse Sost (see Fig. 1D ). The fairly mild osteopenia observed under baseline conditions in SOST Tg mice (see Fig. 1A , B) is in line with the moderate overexpression of SOST under control of the human SOST promoter and distant cis-regulatory elements present in the BAC transgene reaching expression levels within the physiologic range (28) (see Fig. 1C , D).
Skeletal parameters of SOST Tg mice in response to PTH treatment
We analyzed the bone anabolic responses in the tibia and lumbar vertebrae of SOST Tg and wild-type littermate mice relative to vehicle-treated animals using ex vivo whole-bone DXA measurements. Intermittent PTH treatment significantly increased total BMD in the tibia and lumbar spine of wild-type (þ17% and þ14%, respectively) and SOST Tg (þ8% at both sites) mice. However, PTH-induced bone gain was significantly attenuated by about 50% in the appendicular and axial skeleton of SOST Tg compared with wild-type littermate mice ( Fig. 2A, B) .
To characterize PTH-induced bone gain, we determined the percent changes in cross-sectional total BMD and BMC in the distal femur metaphysis relative to baseline using pQCT analyses (see Fig. 2C -E). In wild-type mice, total BMD (see Fig. 2C ) and total BMC (see Fig. 2D ) significantly increased by 20% and 26%, respectively. In SOST Tg littermate mice, intermittent PTH treatment also induced significant increases in total BMD (þ13%; see Fig. 2C ) and total BMC (þ16%; see Fig. 2D ), but the bone anabolic responses clearly were blunted compared with the wild-type littermates.
We then analyzed the bone phenotypic changes in the cortical and cancellous bone compartment of the distal femur metaphysis by pQCT and high-resolution mCT. In wild-type mice, high-dose intermittent PTH treatment significantly increased cross-sectional cortical thickness by 28% relative to baseline (see Fig. 2E , G). Cancellous BMD was significantly augmented by 58% relative to vehicle-treated wild-type littermates (see Fig. 2F , H). In SOST Tg mice, cortical thickness was significantly elevated by 15% relative to baseline in response to intermittent PTH treatment (see Fig. 2E , G), whereas cancellous BMD increased merely in a nonsignificant manner by 27% compared with vehicle-treated transgenic littermates (see Fig. 2F , H). Cancellous bone volume was significantly increased by 73% in PTH-treated wild-type animals, whereas it was only nonsignificantly increased by 29% in PTH-treated SOST Tg mice (Table 1) . Both trabecular number (þ12%) and thickness (þ11%) were significantly increased in PTH-treated wild-type controls, whereas increases were nonsignificant in SOST Tg mice (þ3% and þ7%, respectively; see Table 1 ). Thus relative PTH-induced bone anabolic responses were reduced by about 50% or more in both bone compartments in SOST Tg compared with wild-type littermate males Bone formation and resorption parameters of SOST Tg mice in response to PTH treatment We next analyzed bone formation parameters in the cancellous compartment of the distal femur metaphysis by dynamic bone histomorphometry based on double-fluorochrome-marker incorporation. In PTH-treated wild-type mice, mineralizing surface and mineral apposition rate were significantly elevated by 45% and 67% compared with vehicle-treated littermates, respectively ( Fig. 3B ; see also Table 1 ). Mineralizing surface (þ36%) and mineral apposition rate (þ54%) also were significantly greater in PTH-treated SOST Tg relative to vehicletreated SOST Tg mice, but overall increases were smaller than in PTH-treated wild-type mice, and the mineral apposition rate was significantly lower in SOST Tg mice compared with wild-type mice (see Table 1 and Fig. 3B ). Consequently, while in wild-type mice the bone formation rate was increased by 139% relative to vehicle-treated littermate mice, the PTH-induced increase was significantly less in SOST Tg mice (þ111%; see Fig. 3A ), further demonstrating that elevated SOST expression levels cause a reduction in the bone anabolic response to intermittent PTH treatment. In contrast, the PTH-dependent increase in osteoclast number was comparable between wild-type and SOST Tg mice, and no significant differences were observed in vehicle-or PTHtreated mice of either genotype (see Fig. 3C, D) . Together these data demonstrate that overexpression of SOST, while being PTHresponsive, interferes with the full bone anabolic action of PTH in vivo owing to the higher net Sost expression levels present in SOST Tg mice following intermittent PTH treatment. To further corroborate this finding, we next assessed the skeletal responses to intermittent PTH treatment in homozygous Sost KO mice.
Skeletal parameters of Sost KO mice
Sost KO mice carry a targeted disruption of the 2-exon Sost gene in which the majority of the Sost coding region was replaced by an IRES-LacZ-neomycin/kanamycin resistance cassette (Fig. 4A) . Heterozygous Sost KO (Sost þ/À ) mice were interbred with generate homozygous Sost KO (Sost
) and wild-type offspring (see Fig. 4B ), and their respective bone phenotype was characterized by in vivo pQCT measurements starting at 1 month of age during skeletal growth to skeletal maturity at 4 months of age (see Fig. 4C, D) . Consistent with Sost encoding a potent bone formation inhibitor, homozygous Sost KO mice develop a progressive high bone mass phenotype. From 2 months of age onward, Sost À/À male mice displayed significantly higher cross-sectional total BMD (see Fig. 4C ) and elevated cortical thickness (see Fig. 4D ) in the distal femur metaphysis than their wild-type littermates.
To avoid a situation of saturated bone growth with bone filled marrow cavities possibly present in older Sost À/À mice, we subjected 1.5-month-old Sost À/À male mice and their wild-type littermates to 2 months of treatment with daily injections of 100 mg/kg hPTH(1-34). As expected, Sost expression was completely eliminated in homozygous Sost KO mice in both vehicle-and PTH-treated experimental groups, whereas wildtype littermate mice showed a significant reduction in Sost expression to about 60% of the level of vehicle-treated mice 4 hours after the final PTH application (see Fig. 4E ).
Skeletal parameters of Sost KO mice in response to PTH treatment
We determined the bone phenotypic responses to intermittent PTH treatment using ex vivo whole-bone DXA analyses of the tibia and lumbar vertebrae. As observed previously in skeletally aging mice, 2 months of high-dose intermittent hPTH(1-34) treatment significantly increased total BMD in the appendicular and axial skeleton of skeletally growing wild-type mice by þ16% in the tibia (Fig. 5A ) and þ13% in the lumbar spine (see Fig. 5C ) compared with vehicle-treated littermates, respectively. Total BMD values of the tibia and lumbar vertebrae of vehicle-and PTH-treated Sost À/À mice were significantly higher than those of correspondingly treated wild-type mice. However, PTH-and vehicle-treated Sost À/À littermate mice did not differ significantly in their total BMD at either skeletal site, indicating a distinct blunting of PTH-induced bone anabolism in Sost KO mice.
To study the effects of high-dose PTH treatment in Sost KO mice in more detail, we next characterized the skeletal changes in the femur by ex vivo consecutive pQCT measurements along the femoral axis (see Fig. 5B, D, F) . Femoral cross-sectional total BMD was significantly increased in PTH-relative to vehicletreated wild-type mice, ranging from þ20% in the distal metaphysis to about þ10% at the proximal end of the femoral diaphysis (see Fig. 5B ). Conversely, in Sost À/À mice, intermittent PTH treatment did not result in a significant gain in total BMD at any femoral site analyzed relative to vehicle-treated littermate mice. Likewise, at all evaluated femoral sites, cross-sectional total BMC was significantly elevated in PTH-relative to vehicle-treated wild-type mice, whereas in Sost À/À mice, PTH treatment induced only nonsignificant increases in total BMC compared with vehicle-treated littermate mice (see Fig. 5D ). Thus bone anabolic responses to 2 months of high-dose PTH treatment are strongly attenuated in skeletally growing Sost KO mice.
To determine whether PTH-induced bone anabolism was equally blunted in both bone compartments of Sost À/À mice, we next determined the skeletal responses in femoral cancellous BMD and cross-sectional cortical thickness using ex vivo highresolution mCT and multiple-slice pQCT analyses, respectively. Cross-sectional cortical thickness was significantly increased by about 15% to 40% in PTH-compared with vehicle-treated wildtype mice depending on the respective position analyzed (see Fig. 5F ). In contrast, in Sost À/À mice, no significant gain in crosssectional cortical thickness was detectable in PTH-relative to vehicle-treated mice irrespective of the evaluated femoral site (see Fig. 5F ). Interestingly, we did not detect any net increase in femoral cancellous BMD in response to intermittent PTH treatment in either wild-type or Sost KO mice (see Fig. 5E , G, H), most likely owing to the young age of the mice used in this study in contrast to the aged wild-type and SOST Tg mice described earlier (see Fig. 2F ). Trabecular number actually was significantly lower in either PTH-treated group (À16% in wildtype and À23% in Sost À/À mice, respectively; Table 2 ). Trabecular thickness, however, was significantly increased in PTH-treated groups (þ36% in wild-type and þ31% in Sost À/À mice, respectively), suggesting that increased bone formation occurred in response to PTH treatment. As a net outcome, cancellous bone volume was unchanged in PTH-treated wildtype animals and slightly decreased in PTH-treated Sost À/À mice (À15%; see Table 2 ).
Bone formation and resorption parameters of Sost KO mice in response to PTH treatment littermates (see Table 2 ). In contrast, intermittent PTH treatment caused a significant increase in mineral apposition rates in both wild-type and Sost À/À mice relative to vehicle-treated control littermates ( Fig. 6B ; see also Table 2 ). However, PTH-dependent stimulation of mineral apposition rate increase was reduced by almost 40% in Sost À/À mice (þ42% relative to vehicletreated KO mice) compared with wild-type littermates (þ68% relative to vehicle-treated wild-type mice). As a consequence, ) Sost KO mice. Cross-sectional total BMD (C) and cortical thickness (D) in the distal femur metaphysis of wildtype (white data points) and Sost À/À (filled data points) littermate male mice were evaluated at monthly intervals starting at 1 month of age until skeletal maturity. (E) 4 hours after the final PTH or vehicle application following 2 months of intermittent treatment with 100 mg/ kg hPTH Fig. 6A ). Together these data demonstrate that bone anabolic responses to intermittent PTH treatment are strongly reduced in homozygous Sost KO mice. As in aged mice, osteoclast number was significantly elevated in PTH-relative to vehicle-treated wild-type littermates (þ37%; see Fig. 6C, D) . In PTH-treated Sost KO mice, osteoclast number increased only nonsignificantly compared with vehicle-treated Sost KO mice (þ28%), but no significant differences were detected between genotypes of the same treatment group (see Fig. 6C, D) .
Skeletal parameters of Sost KO mice in response to different anabolic doses of PTH Finally, to exclude the possibility that the observed blunting of PTH-induced bone anabolism in Sost À/À mice was merely a result , and cortical thickness ( F) were assessed by ex vivo pQCT measurements of five consecutive slices S1 to S5 distributed along the femoral axis at equal distances from the distal metaphysis (S1) to the proximal end of the diaphysis (S5). Cancellous BMD in the distal femur metaphysis (E) was evaluated ex vivo by mCT, as illustrated by the 2D (G) and 3D mCT reconstruction images (H). Similar to our previous observations with 100 mg/kg hPTH(1-34) daily dose, PTH-induced increase in cross-sectional total BMD was strongly blunted in Sost À/À mice independent of the PTH dose and skeletal site analyzed. Cross-sectional total BMD in the proximal tibia metaphysis was only nonsignificantly increased by about 5% to 6% in PTH-relative to vehicle-treated Sost À/À mice (Fig. 7A) . In contrast, wild-type mice revealed a significant 12% and 19% increase in cross-sectional total BMD in responses to 2 months of intermittent treatment with daily doses of 40 or 80 mg/kg hPTH(1-34), respectively (see Fig. 7A ). Furthermore, using multiple-slice pQCT measurements along the femoral axis, we found only small, nonsignificant changes in cross-sectional total BMD and BMC in Sost À/À mice, whereas in wild-type mice treated with daily doses of 40 or 80 mg/kg hPTH(1-34), total BMD was elevated by 6% to 24% and total BMC by 11% to 26% relative to vehicle-treated littermates depending on the respective dose and femoral site analyzed (see Fig. 7C, D) . As with 100 mg/kg hPTH(1-34) intermittent treatment, no net cancellous bone gain was noticeable in either genotype compared with vehicletreated control mice (Table 3 ; see also Fig. 7B ). Similar to the previous study, we observed mainly PTH-induced cortical bone gain by about 6% to 28% in wild-type mice depending on the respective dose and femoral site analyzed, which was blunted in Sost À/À mice (see Fig. 7E ). Consistent with the previous study, trabecular number was significantly lower in all PTH-treated groups (see Table 3 ). Trabecular thickness, however, was significantly increased in PTH-treated groups [þ29% and 32% in wild-type mice and þ13% and þ23% in Sost À/À mice treated with 40 or 80 mg/kg hPTH(1-34), respectively], suggesting that increased bone formation occurred in response to PTH treatment.
Discussion
Recently, we and others found that PTH suppresses transcription of the osteocyte-specific bone formation inhibitor Sost. (11, 12) Moreover, PTH treatment results in a decrease in the number of osteocytes expressing sclerostin, the protein product of the Sost gene. (12, 29) Here, we show that PTH-induced bone anabolism is attenuated in mice with altered Sost expression levels. In aging SOST Tg mice, PTH-induced cortical and cancellous bone gain was attenuated in a comparable manner. These mice are expected to express higher net levels of sclerostin protein owing to the presence of the human SOST transgene. Therefore, the observed blunting of bone apposition indicates that for the full PTH bone anabolic response, Sost expression has to be reduced to a threshold below the level present in SOST Tg mice following PTH application. Accordingly, one might speculate that the absolute Sost expression level attained by PTH suppression is of more relevance than the relative difference in Sost expression levels induced by PTH signaling. At the molecular level, PTH application downregulated transgenic human SOST expression by about 50%, similar to endogenous mouse Sost expression, suggesting evolutionary conservation of PTH-induced suppression of SOST, an observation of putative importance concerning the mechanism of action of intermittent PTH treatment applied in the clinic. It is conceivable that PTH-induced suppression of SOST is mediated in part via the distant downstream bone enhancer also present in the SOST BAC transgene of SOST Tg mice. Consistently, we recently identified a conserved myocyte enhancer factor 2 (MEF2) response element in the distant SOST bone enhancer that is required for enhancer activity and is sufficient to mediate PTH-mediated suppression of SOST enhancer activity in vitro. (30) In this respect, it will be interesting to address in future studies the relevance of the distant SOST bone enhancer and the role of MEF2 transcription factors for PTH-induced bone anabolism in vivo. While PTH-induced cancellous bone volume gain was clearly blunted in SOST Tg mice, similar to the observed blunting in the cortical bone compartment, PTH-dependent increase in cancellous bone formation rate was comparatively less strongly attenuated. This could be explained by partly altered kinetics of induction of PTH-dependent anabolism in wild-type versus SOST Tg mice and/or by the reduced cancellous bone template present in osteopenic SOST Tg mice at baseline. Along this line, it has been suggested that PTH treatment is less effective at skeletal sites with a lower amount of preexisting trabecular bone. (31) Moreover, we cannot exclude that Sost inhibits not only bone anabolic pathways acting downstream of PTH but also affects parallel bone anabolic pathways independent of PTH action. However, bone formation rates did not differ between vehicle-treated wild-type and SOST Tg mice, whereas they were attenuated in PTH-treated SOST Tg mice compared with treated , and cortical thickness (E) were evaluated by ex vivo pQCT analyses of five consecutive slices S1 to S5 distributed along the femoral axis at equal distances from the distal metaphysis (S1) to the proximal end of the diaphysis (S5). Data represent means AE SEM. wild-type mice. Hence it seems unlikely that the observed blunting of PTH-induced bone gain in SOST Tg mice was merely the result of an independent superimposed negative effect on parallel bone anabolic pathways. To further consolidate this interpretation, we analyzed PTH-induced bone anabolism in Sost KO mice lacking Sost expression constitutively. If bone anabolic pathways inhibited by Sost action differed from bone anabolic pathways activated by intermittent PTH treatment, we would have expected to observe additive effects of PTH-induced bone anabolism and Sost loss-of-function-dependent bone gain. Instead, we found that PTH-induced bone gain was severely impaired in the skeleton of growing homozygous Sost KO mice, providing further evidence that Sost suppression contributes to PTH-induced bone gain. Morphologically, PTH bone anabolic action appears to rely in part on the reactivation of quiescent lining cells into boneforming cells that contribute to PTH-induced increase in mineralizing bone surface. (7, 32) In addition, PTH-induced expansion of mineralizing bone surface is thought to result from increases in osteoblast number via enhanced osteoblastic precursor proliferation and/or differentiation, (5, 6, 10) as well as reduced osteoblast apoptosis. (8, 9) In wild-type as well as in SOST Tg mice, the relative mineralizing surface increased to 65% to 70% in response to 2 months of high-dose intermittent PTH treatment. This corresponds to the level of mineralizing bone surface present in vehicle-treated homozygous Sost KO mice, which did not further expand in PTH-treated Sost KO littermates, raising the issue of whether an inherent biologic limit exists in vivo that restricts the extent of active bone forming surface. Presently, we cannot fully exclude that the severe blunting of the PTH-induced increase in mineralizing surface observed in Sost KO mice is partly due to such a putative inherent saturation point reached in homozygous Sost KO animals. However, the observed blunting of osteoblastic mineral apposition rate in PTH-treated SOST Tg mice cannot be explained by such a hypothetical mechanism. Moreover, while being attenuated, intermittent PTH treatment still increased mineral apposition rate in Sost KO mice, indicating that bone formation had not reached a terminal saturation point in Sost KO mice. Importantly, PTH-induced bone gain also was strongly blunted in Sost KO mice treated with lower doses of hPTH , excluding that the observed reduction of PTH-induced bone gain in homozygous Sost KO mice was only due to excessive stimulation of bone anabolic pathways triggered by the high PTH dose. Finally, since Sost KO mice display an elevated matrix apposition rate and mineralizing bone surface, it appears that Sost inhibits osteoblastic bone matrix deposition as well as negatively regulates osteoblast recruitment and/or survival consistent with previous findings. (21, 33, 34) The present study suggests that both aspects of Sost action are of relevance for PTH-induced bone anabolism because either was affected by altered Sost gene dosage. Unexpectedly, we did not observe any net increase in femoral cancellous BMD in growing wild-type and Sost KO mice subjected to intermittent PTH treatment in two independent studies. Nonetheless, trabecular thickness and cancellous bone formation rates increased in a manner comparable with the elevated cortical thickness and total BMD gain observed in wildtype mice at all skeletal sites. Thus it appears that intermittent PTH treatment stimulated bone formation responses in both bone compartments to a similar extent but failed to induce sustainable cancellous bone gain. Failure to achieve net cancellous bone gain was related to a decrease in trabecular number in PTH-treated animals of either genotype. Moreover, osteoclast number increased significantly in PTH-treated wildtype and nonsignificantly in PTH-treated Sost KO mice, indicating that the rarefied trabecular number was the consequence of PTH-stimulated enhanced bone resorption. Interestingly, while PTH-induced percentage increase in osteoclast number was similar or even slightly higher in aged wild-type and SOST Tg mice at the end of the treatment period, this did not interfere with overall cancellous bone gain in these animals. Thus it appears that net cancellous bone gain induced by intermittent PTH treatment is regulated by additional factors that might vary with age. Indeed, the number of bone resorbing osteoclasts was approximately doubled in young wild-type and Sost deficient animals compared with aged wild-type and SOST Tg mice irrespective of treatment. Another aspect that might contribute to these variations is the difference in genetic background. This notion is supported by the variability in skeletal responses to intermittent PTH treatment observed in different mouse strains. (31, 35) Since net cancellous bone gain was undetectable in PTH-treated mice of either genotype and bone resorption parameters were comparable between genotypes of the same treatment group, Sost does not appear to have a major impact on PTH-induced bone resorption. Similarly, we did not detect any significant differences in osteoclast number comparing wild-type and SOST Tg mice or the relative PTH-triggered increases thereof, consistent with previous findings implicating Sost in the regulation of bone formation but not bone resorption. (20, 21) In contrast to the net bone anabolic action of intermittent PTH treatment, continuous PTH application is mostly bone catabolic owing to increased bone turnover, with elevated osteoclastic bone resorption exceeding the PTH-induced osteoblastic bone formation increase, (36, 37) whereas osteocytic Sost expression is suppressed in both situations. (12) Recently, the role of PTH signaling in osteocytes was addressed in mice overexpressing a constitutively active PTH1R variant selectively in osteocytes, mimicking part of the effects triggered by continuous systemic PTH exposure in vivo. (13) These transgenic mice displayed a bone-overgrowth phenotype that was characterized by elevated bone turnover, decreased Sost expression, and increased Wnt signaling. In adult bone, Sost-encoded sclerostin is speculated to function as a secreted inhibitor of b-catenin-dependent canonical Wnt signaling by binding to Lrp5 and Lrp6 Wnt coreceptors, preventing their association with the Wnt-Frizzled receptor complex. (38, 39) Given the importance of b-catenindependent canonical Wnt signaling for bone homeostasis, (40) (41) (42) (43) the role of Wnt signaling in PTH-induced bone anabolism has been addressed previously in vivo. (44) (45) (46) Similar to the findings presented here for Sost KO mice, deletion of the Wnt signaling antagonist secreted frizzled-related protein 1 attenuates PTHinduced bone anabolism in vivo, (46) suggesting that activation of Wnt signaling contributes to PTH bone anabolic action. In addition, accumulating in vitro and in vivo evidence suggests a possible role for direct interaction of PTH1R and canonical Wnt signaling pathways. (47) (48) (49) (50) Together, these findings point to potential mechanisms as to why PTH-induced suppression of Sost might be required for the full bone anabolic action of PTH in vivo. In summary, we have shown in the present study that the in vivo bone anabolic action of intermittent PTH treatment is attenuated in Sost gain-and loss-of-function mouse models. Thus PTH-mediated suppression of the PTH downstream target Sost appears to contribute to PTH-induced bone gain in vivo. 
